205 related articles for article (PubMed ID: 38244135)
21. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
22. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
[TBL] [Abstract][Full Text] [Related]
24. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
[TBL] [Abstract][Full Text] [Related]
25. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
Rühle A; Andratschke N; Siva S; Guckenberger M
Clin Transl Radiat Oncol; 2019 Sep; 18():104-112. PubMed ID: 31341985
[TBL] [Abstract][Full Text] [Related]
26. The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer.
Dohopolski M; Hannan R; Wardak Z; Hammers H; Garant A
Cancer J; 2020; 26(5):448-459. PubMed ID: 32947313
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.
Kothari G; Foroudi F; Gill S; Corcoran NM; Siva S
Acta Oncol; 2015 Feb; 54(2):148-57. PubMed ID: 25140860
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
[TBL] [Abstract][Full Text] [Related]
30. Current Role of Radiotherapy for Renal-Cell Carcinoma: Review.
Dengina N; Tsimafeyeu I; Mitin T
Clin Genitourin Cancer; 2017 Apr; 15(2):183-187. PubMed ID: 27789182
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiation therapy for kidney cancer. Where do we stand?
Sosa-Fajardo P; Blanco-Suarez JM; Pineda-Munguía Á; Rubí-Olea L; Peleteiro-Higuero P; Gajate P; Zafra-Martín J; Siva S; Bossi A; López-Campos F; Couñago F
Int J Urol; 2023 May; 30(5):437-445. PubMed ID: 36746747
[TBL] [Abstract][Full Text] [Related]
33. The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma.
Cheung P; Thibault I; Bjarnason GA
Curr Opin Support Palliat Care; 2014 Sep; 8(3):258-64. PubMed ID: 25090288
[TBL] [Abstract][Full Text] [Related]
34. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma.
Siva S; Pham D; Gill S; Corcoran NM; Foroudi F
BJU Int; 2012 Dec; 110(11 Pt B):E737-43. PubMed ID: 23107102
[TBL] [Abstract][Full Text] [Related]
35. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
36. Adding Stereotactic Radiation to the Multidisciplinary Armamentarium for Localized Renal Cell Carcinoma: Ready for Primetime? : An Editorial Regarding a Recent 5-Year Efficacy and Safety Report of a Multicenter Cohort of Primary RCC Patients Treated with SABR.
Koehne EL; Psutka SP
Ann Surg Oncol; 2023 Nov; 30(12):6947-6949. PubMed ID: 37335349
[No Abstract] [Full Text] [Related]
37. Stereotactic body radiotherapy for inoperable patients with renal carcinoma.
Kotzki L; Udrescu C; Lapierre A; Badet L; Rouviere O; Paparel P; Chapet O
Fr J Urol; 2024 Mar; 34(2):102575. PubMed ID: 38364353
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases.
Kothari G; Louie AV; Pryor D; Vela I; Lo SS; Teh BS; Siva S
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S17. PubMed ID: 28917255
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus.
Freifeld Y; Pedrosa I; Mclaughlin M; Correa RM; Louie AV; Maldonado JA; Tang C; Kadow B; Kutikov A; Uzzo RG; Porta C; Bucknell NW; Siva S; Brugarolas J; Margulis V; Timmerman R; Hannan R
Urol Oncol; 2022 Apr; 40(4):166.e9-166.e13. PubMed ID: 35144866
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
Siva S; Louie AV; Kotecha R; Barber MN; Ali M; Zhang Z; Guckenberger M; Kim MS; Scorsetti M; Tree AC; Slotman BJ; Sahgal A; Lo SS
Lancet Oncol; 2024 Jan; 25(1):e18-e28. PubMed ID: 38181809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
